Christopher Thomas Giordano - Dec 10, 2024 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
CEO, Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Stock symbol
TENX
Transactions as of
Dec 10, 2024
Transactions value $
$0
Form type
4
Date filed
12/12/2024, 08:02 PM
Previous filing
May 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +1.25M $0.00 1.25M Dec 10, 2024 Common Stock 1.25M $5.94 Direct
holding TENX Stock Option (right to buy) 157 Dec 10, 2024 Common Stock 157 $3,152.00 Direct F1
holding TENX Stock Option (right to buy) 125 Dec 10, 2024 Common Stock 125 $992.00 Direct F2
holding TENX Stock Option (right to buy) 437 Dec 10, 2024 Common Stock 437 $3.55 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
F2 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F3 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.